# Immuneering (IMRX) — News

IMRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imrx/news

## Recent headlines

- [Immuneering Corporation: H.C. Wainwright initiates coverage with buy rating](https://www.ainvest.com/news/immuneering-corporation-wainwright-initiates-coverage-buy-rating-2608) — AInvest Wire, Aug 6, 2026
- [Immuneering Corporation Q2 EPS USD -0.27 vs. IBES estimate USD -0.27](https://www.ainvest.com/news/immuneering-corporation-q2-eps-usd-0-27-ibes-estimate-usd-0-27-2608) — AInvest Wire, Aug 5, 2026
- [Immuneering Corp: Needham raises target price to $18 from $11](https://www.ainvest.com/news/immuneering-corp-needham-raises-target-price-18-11-2607) — AInvest Wire, Jul 20, 2026
  Needham & Co. has raised its price target for Immuneering Corporation (NASDAQ:IMRX) to $18 from $11, maintaining a Buy rating on the stock. This adjustment follows recent developments, including the company’s $25 million private placement and a clinical collaboration with Eli Lilly to evaluate…
- **Important** — Immuneering announces FDA clears INDA for phase 1/2A trial of IMM-6-415 — AInvest Wire, Dec 12, 2023

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).